Amicus Therapeutics Inc. (FOLD)

13.57
0.22 1.60
NASDAQ : Health Technology
Prev Close 13.79
Open 13.81
Day Low/High 13.30 / 13.87
52 Wk Low/High 6.41 / 17.40
Volume 1.90M
Avg Volume 3.03M
Exchange NASDAQ
Shares Outstanding 187.97M
Market Cap 2.63B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Amicus Therapeutics Announces Approval Of Galafold® (Migalastat) For Fabry Disease In Japan

Amicus Therapeutics Announces Approval Of Galafold® (Migalastat) For Fabry Disease In Japan

First Amicus Medicine and First Oral Precision Medicine for Fabry Patients with an Amenable Mutation in Japan

Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives To Change People's Lives Living With Rare Diseases

Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives To Change People's Lives Living With Rare Diseases

Unique Volunteerism, Mentorship, Giving, Global Access and Advocacy Programs Under Long-term Healing Beyond Disease Initiatives

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

Six-Month PDUFA Goal Date is August 13, 2018

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Amicus Therapeutics Appoints Michael C. Diem, MD As Senior Vice President Of Business And Corporate Development

Amicus Therapeutics Appoints Michael C. Diem, MD As Senior Vice President Of Business And Corporate Development

Driven Business Executive with Strong Industry Track Record

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.

Bank Funds Fall Short on the Upside

After Fed decision, buying interest looks weak.

TheStreet Quant Rating: D- (Sell)